CN1821271A - 一种抗菌肽及其编码序列和用途 - Google Patents
一种抗菌肽及其编码序列和用途 Download PDFInfo
- Publication number
- CN1821271A CN1821271A CN 200510121037 CN200510121037A CN1821271A CN 1821271 A CN1821271 A CN 1821271A CN 200510121037 CN200510121037 CN 200510121037 CN 200510121037 A CN200510121037 A CN 200510121037A CN 1821271 A CN1821271 A CN 1821271A
- Authority
- CN
- China
- Prior art keywords
- antibacterial peptide
- sequence
- site
- seq
- cdna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003115 biocidal effect Effects 0.000 title abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 title description 10
- 241000894006 Bacteria Species 0.000 claims abstract description 19
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 19
- 239000002157 polynucleotide Substances 0.000 claims abstract description 19
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 19
- 239000002773 nucleotide Substances 0.000 claims abstract description 12
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 12
- 230000000295 complement effect Effects 0.000 claims abstract description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 53
- 239000013604 expression vector Substances 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 8
- 230000002147 killing effect Effects 0.000 abstract description 7
- 241000607265 Vibrio vulnificus Species 0.000 abstract description 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 abstract 1
- 239000003899 bactericide agent Substances 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 16
- 241000357444 Epinephelus coioides Species 0.000 description 15
- 235000019688 fish Nutrition 0.000 description 15
- 241000251468 Actinopterygii Species 0.000 description 14
- 239000000047 product Substances 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000000845 anti-microbial effect Effects 0.000 description 7
- 238000013016 damping Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000321428 Epinephelus guttatus Species 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000009360 aquaculture Methods 0.000 description 5
- 244000144974 aquaculture Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 230000009465 prokaryotic expression Effects 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000607598 Vibrio Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 108050004290 Cecropin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- QBLMTCRYYTVUQY-GUBZILKMSA-N Gln-Leu-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O QBLMTCRYYTVUQY-GUBZILKMSA-N 0.000 description 2
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 241000544286 Vibrio anguillarum Species 0.000 description 2
- 206010047400 Vibrio infections Diseases 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 108010045383 histidyl-glycyl-glutamic acid Proteins 0.000 description 2
- 108010036413 histidylglycine Proteins 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 235000014102 seafood Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VBRDBGCROKWTPV-XHNCKOQMSA-N Ala-Glu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N VBRDBGCROKWTPV-XHNCKOQMSA-N 0.000 description 1
- NMXKFWOEASXOGB-QSFUFRPTSA-N Ala-Ile-His Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 NMXKFWOEASXOGB-QSFUFRPTSA-N 0.000 description 1
- LBYMZCVBOKYZNS-CIUDSAMLSA-N Ala-Leu-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O LBYMZCVBOKYZNS-CIUDSAMLSA-N 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- MSILNNHVVMMTHZ-UWVGGRQHSA-N Arg-His-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CN=CN1 MSILNNHVVMMTHZ-UWVGGRQHSA-N 0.000 description 1
- 241000251557 Ascidiacea Species 0.000 description 1
- IJHUZMGJRGNXIW-CIUDSAMLSA-N Asp-Glu-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IJHUZMGJRGNXIW-CIUDSAMLSA-N 0.000 description 1
- DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 244000097582 Cecropia peltata Species 0.000 description 1
- 241000252185 Cobitidae Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- KKUVRYLJEXJSGX-MXAVVETBSA-N Cys-Ile-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CS)N KKUVRYLJEXJSGX-MXAVVETBSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241001600125 Delftia acidovorans Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- AVZHGSCDKIQZPQ-CIUDSAMLSA-N Glu-Arg-Ala Chemical compound C[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O AVZHGSCDKIQZPQ-CIUDSAMLSA-N 0.000 description 1
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 1
- YMUFWNJHVPQNQD-ZKWXMUAHSA-N Gly-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN YMUFWNJHVPQNQD-ZKWXMUAHSA-N 0.000 description 1
- VXKCPBPQEKKERH-IUCAKERBSA-N Gly-Arg-Pro Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N1CCC[C@H]1C(O)=O VXKCPBPQEKKERH-IUCAKERBSA-N 0.000 description 1
- BIRKKBCSAIHDDF-WDSKDSINSA-N Gly-Glu-Cys Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O BIRKKBCSAIHDDF-WDSKDSINSA-N 0.000 description 1
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
- GAFKBWKVXNERFA-QWRGUYRKSA-N Gly-Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 GAFKBWKVXNERFA-QWRGUYRKSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- HAPWZEVRQYGLSG-IUCAKERBSA-N His-Gly-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O HAPWZEVRQYGLSG-IUCAKERBSA-N 0.000 description 1
- RGPWUJOMKFYFSR-QWRGUYRKSA-N His-Gly-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O RGPWUJOMKFYFSR-QWRGUYRKSA-N 0.000 description 1
- CGAMSLMBYJHMDY-ONGXEEELSA-N His-Val-Gly Chemical compound CC(C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N CGAMSLMBYJHMDY-ONGXEEELSA-N 0.000 description 1
- UAELWXJFLZBKQS-WHOFXGATSA-N Ile-Phe-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(O)=O UAELWXJFLZBKQS-WHOFXGATSA-N 0.000 description 1
- DLFAACQHIRSQGG-CIUDSAMLSA-N Leu-Asp-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O DLFAACQHIRSQGG-CIUDSAMLSA-N 0.000 description 1
- QLQHWWCSCLZUMA-KKUMJFAQSA-N Leu-Asp-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QLQHWWCSCLZUMA-KKUMJFAQSA-N 0.000 description 1
- KVMULWOHPPMHHE-DCAQKATOSA-N Leu-Glu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KVMULWOHPPMHHE-DCAQKATOSA-N 0.000 description 1
- CFZZDVMBRYFFNU-QWRGUYRKSA-N Leu-His-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(O)=O CFZZDVMBRYFFNU-QWRGUYRKSA-N 0.000 description 1
- JFSGIJSCJFQGSZ-MXAVVETBSA-N Leu-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC(C)C)N JFSGIJSCJFQGSZ-MXAVVETBSA-N 0.000 description 1
- KYIIALJHAOIAHF-KKUMJFAQSA-N Leu-Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 KYIIALJHAOIAHF-KKUMJFAQSA-N 0.000 description 1
- FBNPMTNBFFAMMH-AVGNSLFASA-N Leu-Val-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-AVGNSLFASA-N 0.000 description 1
- 241000269970 Limanda ferruginea Species 0.000 description 1
- WVJNGSFKBKOKRV-AJNGGQMLSA-N Lys-Leu-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVJNGSFKBKOKRV-AJNGGQMLSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- ONGCSGVHCSAATF-CIUDSAMLSA-N Met-Ala-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O ONGCSGVHCSAATF-CIUDSAMLSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000269799 Perca fluviatilis Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000276427 Poecilia reticulata Species 0.000 description 1
- DMKWYMWNEKIPFC-IUCAKERBSA-N Pro-Gly-Arg Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O DMKWYMWNEKIPFC-IUCAKERBSA-N 0.000 description 1
- VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 description 1
- XQSREVQDGCPFRJ-STQMWFEESA-N Pro-Gly-Phe Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O XQSREVQDGCPFRJ-STQMWFEESA-N 0.000 description 1
- 241000589614 Pseudomonas stutzeri Species 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000736110 Sphingomonas paucimobilis Species 0.000 description 1
- 241001494106 Stenotomus chrysops Species 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- VTFWAGGJDRSQFG-MELADBBJSA-N Tyr-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O VTFWAGGJDRSQFG-MELADBBJSA-N 0.000 description 1
- WGHVMKFREWGCGR-SRVKXCTJSA-N Val-Arg-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WGHVMKFREWGCGR-SRVKXCTJSA-N 0.000 description 1
- SYOMXKPPFZRELL-ONGXEEELSA-N Val-Gly-Lys Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N SYOMXKPPFZRELL-ONGXEEELSA-N 0.000 description 1
- BTWMICVCQLKKNR-DCAQKATOSA-N Val-Leu-Ser Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C([O-])=O BTWMICVCQLKKNR-DCAQKATOSA-N 0.000 description 1
- XNLUVJPMPAZHCY-JYJNAYRXSA-N Val-Val-Phe Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 XNLUVJPMPAZHCY-JYJNAYRXSA-N 0.000 description 1
- 241000607594 Vibrio alginolyticus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
本发明提供了一种抗菌肽、编码该抗菌肽的多核苷酸以及该抗菌肽的用途。该抗菌肽是含有序列表SEQ ID NO:2中1至23位的氨基酸序列。编码该抗菌肽的多核苷酸是含有编码序列表SEQ ID NO:2中1至23位、1至49位或-22至49位的氨基酸序列的核苷酸序列或它们的互补序列。该抗菌肽对多种细菌(包括多种水产细菌)有明显的杀灭作用,对副溶血弧菌、溶藻弧菌、美人鱼弧菌、摩根尔摩根菌、食酸假单胞菌、创伤弧菌、脑膜炎脓毒性黄杆菌、少动假单胞菌、施氏假单胞菌的最低杀死浓度达小于10μmol/L,可用于制备抗菌剂或杀菌剂,特别是用于水产养殖中预防和治疗细菌性疾病。
Description
技术领域
本发明涉及一种抗菌肽,特别是斜带石斑鱼抗菌肽,编码该抗菌肽的核苷酸序列以及该抗菌肽的用途。
背景技术
抗菌肽(antimicrobial peptide)是具有抗菌性短肽的总称。1981年瑞典科学家Steiner等从惜古比天蚕(Hyatophora cecropia)蛹中分离得到一种杀菌肽,并将其命名为cecropin。到目前,已发现抗菌肽和类似抗菌肽的小分子短肽广泛存在于生物界,包括细菌、动植物和人类。这种内源性的抗菌肽经诱导而合成,在机体抵抗病原体的入侵方面起着重要作用。抗菌肽具有广谱杀菌作用,大多数对革兰氏阳性菌有较杀灭作用,有些则对革兰氏阳性菌和阴性菌均起作用,对某些真菌、原生动物、尤其对耐药性细菌有杀灭作用。
随着人们生活水平的提高,对海产品的需求愈来愈大。石斑鱼是驰名世界的名贵海产鱼类之一,其肉质鲜美,营养丰富,深受各地消费者的喜爱。由于养殖密度不断增高,以及人类活动的影响、环境的污染,造成石斑鱼的育苗和养成过程受到病毒、细菌和寄生虫的袭击,造成养殖成活率低于50%,成为制约石斑鱼养殖业发展的主要因素。
对于细菌病,目前主要应用抗生素进行防治。后果造成了环境污染;使鱼的品质口味下降;同时病原体的抗药性增强,使化学药物和抗生素的用量越来越大,但病害问题并未解决;农药和抗生素的残留影响了水产品的质量,如日本和欧盟国家都曾因抗生素残留问题而拒绝进口中国的水产品。寻找新的生物防治的方法,调动和开发石斑鱼自身的免疫防御潜力,是保证食品安全和环境安全的必要手段,是开展健康养殖、实现养殖业可持续发展的重要战略。
鱼类生活于富含各种各样微生物的水环境中,长期的生存适应使其形成了有效的防御机制。鱼类天然免疫是抵抗感染的第一道防线,能有效阻止微生物的吸附、侵入与复制。由于是非特异的,不必依赖于对病原特异分子结构的识别,因而可对多种入侵病原发生反应;而且这种反应迅速,没有时间延迟,即便是经过诱导产生也只有很短的时间延缓,这样给病原体留下较少的生存时间。目前认为,非特异性天然免疫对于鱼类比对于恒温动物更为重要,在抵抗感染中发挥重要作用。
随着研究的深入,一些重要的鱼类抗菌肽基因正陆续被克隆。现己从美洲黄盖鲽、鲈鱼、真鲷中克隆到一些抗菌肽基因。另从一些鱼类中获得了具有抗菌肽活性的肽,如豹鳎、海士鳃鳗、海鞘、泥鳅、鲶等。研究表明,鱼类抗菌肽是鱼体非特异性免疫系统的重要组成部分,当鱼体受到损伤或病原微生物侵袭时,能迅速产生抗菌肽以预防和杀伤病原微生物的入侵。其合成速度快,在体内扩散迅速、灵活的特点是其它大分子蛋白(如抗体)和免疫细胞所不具备的。
目前研究证实许多抗菌肽对鱼类特异性的甚至其它动物的病原微生物都具有杀伤活性。最低杀死浓度多在微摩尔水平。Jia等发现cecropin-melittin重组肽和C端酰胺化的pleurocidin可保护银大麻哈鱼抵御鳗弧菌(Vibrio anguillarum)的感染。随着对水产养殖品种抗菌肽的分离、结构与功能的研究,改造并合成既具有稳定高效抗菌活性又具特异抗菌谱且同时对宿主无害的抗菌肽基因,并通过基因工程在原核细胞、真核细胞或某些藻类中进行表达,以批量生产,将有希望成为对付水产养殖品种主要病原体特别是耐药菌的新型药物。
发明内容
本发明的目的是提供一种新的抗菌肽,以及编码该抗菌肽的核苷酸序列和该抗菌肽的用途。
本发明通过构建斜带石斑鱼白细胞cDNA文库,并通过测序和筛选,获得了一种斜带石斑鱼抗菌肽的cDNA。同时,通过人工合成方法和原核表达载体重组表达方法,分别获得了该抗菌肽cDNA所编码的多肽片段,并经试验证明该多肽片段具有较强的抗菌作用,是一种新的抗菌肽。
本发明的抗菌肽,其特征在于,它含有序列表sEQ ID NO:2中1至23位的氨基酸序列。它可以是序列表SEQ ID NO:2中1至23位、1至49位或-22至49位的氨基酸序列。优选为序列表SEQ ID NO:2中1至23位的氨基酸序列。
本发明还提供编码以上所述抗菌肽的多核苷酸。该多核苷酸含有编码序列表SEQ ID NO:2中1至23位、1至49位或-22至49位的氨基酸序列的核苷酸序列或它们的互补序列。可以是序列表SEQ ID NO:1的核苷酸序列或其中的156~224位多核苷酸,或它们的互补序列。序列表SEQ ID NO:3是SEQ ID NO:1核苷酸序列的互补序列。
本发明还提供一种表达载体,它含有编码以上所述抗菌肽的多核苷酸。该多核苷酸可以是含有编码序列表SEQ ID NO:2中1至23位、1至49位或-22至49位的氨基酸序列的核苷酸序列或它们的互补序列;可以是序列表SEQ ID NO:1的核苷酸序列或其中的156~224位多核苷酸,或它们的互补序列。该表达载体可以是在原核表达载体prSET A(购自Invitrogen公司)的多酶切位点插入上述的多核苷酸而构建成的表达质粒。
本发明还提供一种重组工程菌,它含上述的表达载体。它可以是将上述的表达载体转化大肠杆菌(例如大肠杆菌BL21)而得到。
本发明经实验证明,上述本发明的抗菌肽,对多种细菌(包括多种水产细菌)有较强的杀灭作用(参见实施例二,表1)。因此,该抗菌肽可用于制备细菌抗菌剂,特别是用于制备预防和治疗水生生物细菌病的抗菌剂。
本发明的抗菌肽可通过以下方法制备:
1.根据所述抗菌肽的氨基酸序列(例如SEQ ID NO:2中1~23位氨基酸残基的序列),用固相合成法合成多肽,并将C端酰胺化。
2.将编码所述抗菌肽的核苷酸序列(例如SEQ ID NO:1中156~224位的多核苷酸)克隆入重组表达载体,并将重组后的DNA转化入宿主细胞,进行重组表达。纯化后获得该抗菌肽。
本发明的抗菌肽及其多核苷酸序列还具有下列用途:
1.在水产养殖业中的应用:该抗菌肽可通过浸泡、注射、添加于饲料等方法,用来预防和治疗鱼类或其它水生生物的细菌性疾病。
2.该抗菌肽与牛血清白蛋白偶联后免疫动物,可以制备与抗菌肽特异性结合的抗体。该抗体可以用于检测溶液中抗菌肽的存在,及通过免疫组化的方法检测抗菌肽在鱼体内不同组织的表达情况。
3.将SEQ ID NO:1或与其互补的多核苷酸(包括DNA或RNA),或其片段,进行标记后,可以通过Southern印迹、Northern印迹、基因芯片、微陈列等技术,检测动物基因组中抗菌肽基因片段的存在,或检测抗菌肽基因的转录情况。
4.根据SEQ ID NO:1或与其互补的多核苷酸设计引物,可通过反转录-聚合酶链反应(RT-PCR)检测抗菌肽基因在动物体内各组织中、不同发育阶段的转录情况
下面结合具体实施例对本发明作进一步具体说明。
具体实施方式
实施例一:斜带石斑鱼抗菌肽cDNA的获取
本发明人用Clontech公司SMARTcDNA文库构建试剂盒,构建了斜带石斑鱼白细胞cDNA文库,通过随机挑取克隆测序,并将测得序列用BLAST程序与Genbank序列进行比较,获得了抗菌肽的cDNA。
1.斜带石斑鱼白细胞总RNA的提取
健康斜带石斑鱼(重约600g),腹腔注射polyI:C(购自Amersham Pharmacia)0.4ml,浓度为2mg/ml。72h后,从尾静脉抽血,加至四倍体积含肝素的生理盐水。将此悬液缓慢加在二倍悬液体积的Ficoll-Paque Plus淋巴细胞分离液(购自Amersham Pharmacia)的表面。平衡后于室温400g离心30min。吸出中间层的白细胞,用生理盐水洗两次,每次于200g离心15min并弃上清。细胞用1ml生理盐水重悬,用细胞计数板计数后,分装至1.5ml离心管中,400g离心2min弃上清。用Tripure试剂(购自Roche Diagnostics公司)提取总RNA。
2.cDNA一链的合成:
总RNA(0.25μg/μl) 3μl
SMART III寡聚核苷酸 1μl
CDS III/3’PCR引物 1μl
总体积 5μl
将以上成分混匀,在离心机上甩一下,于72℃孵育2min。接着置冰浴2min。再在离心机上甩一下,然后于管中依次加入:
5×1st链缓冲液 2.0μl
DTT(20mmol/L) 1.0μl
dNTP mix(10mmol/L) 1.0μl
SUPERSCRIPTTM II反转录酶(200u/μl) 1.0μl
总体积 10.0μl
轻轻吹打混匀以上成分,在离心机上甩一下。加1滴矿物油,于42℃温育1h。取出管子置冰浴终止第一链cDNA合成。
3.cDNA的长距离PCR:
取一0.5ml Eppendorf管依次加入:
1st链cDNA 2μl
去离子水 80μl
10×cDNA PCR缓冲液 10μl
50×dNTP mix 2μl
5’PCR引物 2μl
CDS III/3’PCR引物 2μl
50×Advantage cDNA聚合酶混合物 2μl
总体积 100μl
轻弹管壁混匀以上成分,在离心上甩一下。加2滴矿物油,将反应管置于已预热至95℃C的PCR仪上,进行长距离PCR(LD-PCR)。
反应程序为:(1)95℃1min;(2)95℃15sec,68℃6min,30个循环。
反应完毕,取5μl PCR产物,于1.1%琼脂糖凝胶上,以0.1μg 1kb DNA Ladder为分子量标准进行电泳检测。
4.LD-PCR产物的蛋白酶K消化:
于一灭菌0.5ml管加入50μl LD-PCR产物和2μl蛋白酶K(20μg/μl),混匀,稍离心。将反应管置于45℃孵育20min,稍离心。加50μl去离子水至管中,再加入100μl酚∶氯仿∶异戊醇(25∶24∶1),来回缓慢颠倒1-2min。以14,000×g离心5min。移上层水相至一灭菌0.5ml管,加入10μl 3mol/LNaAc溶液、1.3μl糖原溶液(20μg/μl)、260μl 95%乙醇(室温),立即于室温以14,000×g离心20min。小心移去上清,用100μl 80%乙醇洗涤沉淀。空气干燥沉淀8~10min。接着加入79μl去离子水重悬沉淀。
5.cDNA进行Sfi I酶切:
取一灭菌0.5ml管依次加入:
cDNA 79μl
10×Sfi I缓冲液 10μl
Sfi I酶(20u/μl) 10μl
100×BSA 1μl
总体积 100μl
将管中以上成分充分混合,在离心上甩一下。置于50℃温育2h。接着加入2μl 1%二甲苯青,充分混合。
6.cDNA的分部分离:
取16支1.5ml管,按1-16顺序编号并依次放置在试管架上。将100μl Sfi I酶切的cDNA与二甲苯青混合物小心地逐滴加入到CHROMA SPIN-400柱子中基质表面的中心,让样品被基质充分吸收。用100μl CHROMA柱缓冲液洗柱。待缓冲液流尽后,加入600μl CHROMA柱缓冲液至柱中,立即开始逐滴收集流出的液滴到1#-16#管(约35μl/管)。每管分别取3μl收集液于1.1%琼脂糖凝胶150V电泳10min,以0.1μg 1kb DNA为分子量标准。在紫外灯下观察cDNA带的亮度。将亮度最高的,即cDNA含量最高的3管收集液集中至一1.5ml管,加入1/10体积3mol/L NaAc(pH4.8)、1.3μl糖原(20mg/ml)、2.5倍体积95%乙醇(-20℃),缓慢地来回颠倒。将管置于-20℃放1h。室温下14,000×g离心20min,小心移走上清,空气干燥8~10min,用7μl去离子水重悬沉淀。
7.cDNA与载体的连接
由于难以确定多少量的cDNA与载体连接效果最好,故进行了一系列预连接和包装反应。按如下方法于3个0.5ml管内建立3组连接-包装反应:
1# | 2# | 3# | |
cDNA载体(500ng/μl)10×连接缓冲液ATP(10mmol/L)T4DNA连接酶(400u/μl)去离子水总体积(μl) | 0.51.00.50.50.52.05.0 | 1.01.00.50.50.51.55.0 | 1.51.00.50.50.51.05.0 |
将以上各管混匀后在离心上甩一下,于PCR仪上16℃温育过夜。
8.连接产物的包装:按MaxPlax Lambda包装提取物说明书进行。
9.插入子的PCR扩增:
从文库平板随机挑取单个噬菌斑,加至500μlλ噬菌体稀释液,室温放置1-2h,以使噬菌体从琼脂中释放出来。取1μl噬菌体做模板,用Advantage cDNA PCR试剂盒(Clontech)进行PCR,鉴定插入子的大小。
所用引物:
λTriplEx 5’长距离插入子筛选引物(AP1):5’-CTC GGG AAG CGC GCC ATT GTG TTG GT-3’,
λTriplEx 3’长距离插入子筛选引物(AP2):5’-ATA CGA CTC ACT ATA GGG CGA ATT GGC C-3’
PCR反应混合液:10×PCR缓冲液5μl,AP1和AP2引物(每种10μmol/L)2μl,4×dNTP混合液(每种10mmol/L)1μl,cDNA聚合酶混合物1μl,水40.5μl。
PCR循环参数:94℃,10min;30次循环:94℃,30s;68℃,3min。68℃,3min。PCR结束后取5μl进行琼脂糖凝胶电泳。大于500bp的PCR产物,用PCR产物胶回收试剂盒(购自上海生工生物工程有限公司)进行回收纯化。
10.序列测定:委托上海基康生物工程有限公司完成。
11.测序结果的分析:
用美国国立生物技术信息中心(NCBI)的BLAST N和BLAST X工具,与GenBank的数据库进行同源性比较。发现一个序列与其它抗菌肽的cDNA有一定的同源性,经分析确认为是斜带石斑鱼的抗菌肽cDNA序列,该序列如序列表SEQ ID NO:1所示。
实施例二:抗菌肽的固相化学合成及最低杀菌浓度的测定
1.抗菌肽的固相化学合成:
按序列表SEQ ID NO:2的1至23位氨基酸残基的序列,委托深圳翰宇生物技术有限公司合成多肽,并将C末端酰胺化。合成后经纯化,达到85%的纯度。
2.最低杀菌浓度的测定
将不同细菌用营养肉汤液体培养基于37℃振荡培养过夜。将过夜菌用营养肉汤液体培养基稀释至约2×105克隆形成单位每毫升(CFU ml-1)。分别取25μl菌液与等体积不同浓度的用1mmol/L醋酸缓冲液(pH4.0)稀释的上述合成得到的抗菌肽溶液(400μg/ml至0.5μg/ml)在96孔细胞培养板孔中混匀,菌液与等体积醋酸缓冲液混匀做为对照,放于细菌培养箱中37℃温育1h,然后取孔中的液体涂于营养肉汤固体培养基平板,放37℃温育过夜。数出平板上的菌落数目。与对照的平板相比,菌落数小于对照平板1%数目的平板的抗菌肽浓度做为对该菌的最低杀菌浓度(minimal bacteriacideconcentration,MBC)。结果如表1所示。
表1 斜带石斑鱼抗菌肽对一些细菌的最低杀菌浓度
细菌 | MBC(μmol/L) |
副溶血弧菌摩根尔摩根菌食酸假单胞菌创伤弧菌脑膜炎脓毒性黄杆菌溶藻弧菌美人鱼弧菌少动假单胞菌施氏假单胞菌大肠杆菌TG1 | 2.452.452.454.894.894.894.894.894.8939.12 |
如表1所示,该抗菌肽对多种细菌,特别是鱼类最重要的病原菌弧菌类,有很好的杀灭作用,在制备抗菌剂以及鱼类细菌病的预防和治疗方面有着很大的应用前景。
实施例三:石斑鱼抗菌肽在原核表达载体的重组表达
根据SEQ ID NO:1中156~224位多核苷酸的两端序列和原核表达载体pRSET A的多酶切位点,合成一对引物,序列如下:上游引物,5’-GCGGATCC ATC TTT GGA TTG CTT CTC-3’,其中下划线部分为BamHI酶切位点;下游引物,5’-CGGAATTC ATG GCG CCT AAC AAG CCC-3’,其中下划线部分为EcoRI酶切位点。
PCR扩增、基因克隆皆按常规方法进行。PCR产物约80bp。将目的基因(SEQ ID NO:1的核苷酸序列或其中的156~224位多核苷酸)克隆到原核表达载体pRSET A上,构建成表达质粒pRSET-Epi,经酶切鉴定和测序分析表明克隆的基因为目的基因。
将表达质粒pRSET-Epi转化大肠杆菌BL21。含目的基因的工程菌在37℃生长到OD600=0.5时,立即加入终浓度为0.1M的异丙基硫代-β-D-半乳糖苷(IPTG)诱导4小时。收集菌体,经分离纯化得到分子量为6kD的目标蛋白。经免疫印迹表明:所得到的目标蛋白的氨基酸序列与SEQ ID NO:2的N末端相符。
序列表
<110>中山大学
<120>一种抗菌肽及其编码序列和用途
<160>3
<210>1
<211>613
<212>cDNA
<213>斜带石斑鱼(Epinephelus coioides)
<220>
<221>CDS
<222>(90)...(305)
<400>1
gagacacaga tatattacat accctgtgaa tctctcacta ctctgtttga gagcagcctt 60
ttgcctttga ctctgagtca gtggaaagg atg aag tgt act gtg gtc ttt ctt 113
Met Lys Cys Thr Val Val Phe Leu
-20 -15
gtg ttg tcc atg gtc gta ttc atg gct gaa cct gga gag tgt atc ttt 161
Val Leu Ser Met Val Val Phe Met Ala Glu Pro Gly Glu Cys Ile Phe
-10 -5 -11
gga ttg ctt ctc cac gga gcc att cac gtt ggc aaa ctg atc cat ggg 209
Gly Leu Leu Leu His Gly Ala Ile His Val Gly Lys Leu Ile His Gly
5 10 15
ctt gtt agg cgc cat ggg gaa gag cag ctg gat gac cta gag cag ctg 257
Leu Val Arg Arg His Gly Glu Glu Gln Leu Asp Asp Leu Glu Gln Leu
20 25 30
gac gaa cgt gca ctt gat tat aac ccg ggg cgg cct ggt ttt gac tag 305
Asp Glu Arg Ala Leu Asp Tyr Asn Pro Gly Arg Pro Gly Phe Asp ***
35 40 45
actgcggggg caactctgaa gctacatgtt ggatccccgt cgaaaacgag atgctctatc 365
tcaagaggct atcctaaata aattgaattg aattgaatct gaattggatt aaaagatttg 425
cttctggctt cttcctcttc aaaatgagaa agaaaagtgt ctttcaagcg ccagaaacca 485
tcgcttgaaa aacacactga gtgatgataa ccttttgaat taattttggt acagtggcaa 545
gccgtaaaaa ctcaaaataa aataaaaatt gcccttttaa atccatggaa aaaaaaaaaa 605
aaa aaa aa 613
<210>2
<211>71
<212>PRT
<213>斜带石斑鱼(Epinephelus coioides)
<400>2
Met Lys Cys Thr Val Val Phe Leu Val Leu Ser Met Val Val Phe Met
-20 -15 -10
Ala Glu Pro Gly Glu Cys Ile Phe Gly Leu Leu Leu His Gly Ala Ile
-5 -11 5 10
His Val Gly Lys Leu Ile His Gly Leu Val Arg Arg His Gly Glu Glu
15 20 25
Gln Leu Asp Asp Leu Glu Gln Leu Asp Glu Arg Ala Leu Asp Tyr Asn
30 35 40
Pro Gly Arg Pro Gly Phe Asp
45
<210>3
<211>613
<212>cDNA
<213>斜带石斑鱼(Epinephelus coioides)
<400>3
tttttttttt tttttttttt ccatggattt aaaagggcaa tttttatttt attttgagtt 60
tttacggctt gccactgtac caaaattaat tcaaaaggtt atcatcactc agtgtgtttt 120
tcaagcgatg gtttctggcg cttgaaagac acttttcttt ctcattttga agaggaagaa 180
gccagaagca aatcttttaa tccaattcag attcaattca attcaattta tttaggatag 240
cctcttgaga tagagcatct cgttttcgac ggggatccaa catgtagctt cagagttgcc 300
cccgcagtct agtcaaaacc aggccgcccc gggttataat caagtgcacg ttcgtccagc 360
tgctctaggt catccagctg ctcttcccca tggcgcctaa caagcccatg gatcagtttg 420
ccaacgtgaa tggctccgtg gagaagcaat ccaaagatac actctccagg ttcagccatg 480
aatacgacca tggacaacac aagaaagacc acagtacact tcatcctttc cactgactca 540
gagtcaaagg caaaaggctg ctctcaaaca gagtagtgag agattcacag ggtatgtaat 600
atatctgtgt ctc 613
Claims (9)
1.一种抗菌肽,其特征在于,它是SEQ ID NO:2中1至23位的氨基酸序列。
2.一种编码权利要求1所述抗菌肽的多核苷酸。
3.按照权利要求2所述的多核苷酸,其特征在于,它是编码SEQ ID NO:2中1至23位的氨基酸序列的核苷酸序列或它们的互补序列。
4.按照权利要求3所述的多核苷酸,其特征在于,它是SEQ ID NO:1中156至224位的核苷酸序列或其互补序列。
5.一种表达载体,其特征在于,它含有权利要求2,3或4所述的多核苷酸。
6.一种重组工程菌,其特征在于,它含有权利要求5所述的表达载体。
7.按照权利要求6所述的重组工程菌,其特征在于,它是将权利要求5所述的表达载体转化大肠杆菌而得到的。
8.权利要求1所述抗菌肽在制备细菌抗菌剂中的应用。
9.按照权利要求8所述的应用,其特征在于所述抗菌剂是用于预防和治疗水生生物细菌病的抗菌剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101210370A CN100402552C (zh) | 2005-12-29 | 2005-12-29 | 一种抗菌肽及其编码序列和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101210370A CN100402552C (zh) | 2005-12-29 | 2005-12-29 | 一种抗菌肽及其编码序列和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1821271A true CN1821271A (zh) | 2006-08-23 |
CN100402552C CN100402552C (zh) | 2008-07-16 |
Family
ID=36922860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005101210370A Expired - Fee Related CN100402552C (zh) | 2005-12-29 | 2005-12-29 | 一种抗菌肽及其编码序列和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100402552C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102140130A (zh) * | 2010-11-12 | 2011-08-03 | 中国科学院海洋研究所 | 一种抗菌肽及其应用 |
CN118252918A (zh) * | 2024-05-27 | 2024-06-28 | 华南农业大学 | 斜带石斑鱼piscidin3及其合成多肽在制备抗鱼类病毒药物中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1624127A (zh) * | 2004-11-03 | 2005-06-08 | 厦门大学 | 海水养殖真鲷的hepcidin抗菌肽基因 |
CN1632120A (zh) * | 2004-11-03 | 2005-06-29 | 厦门大学 | 海水养殖鲈鱼的hepcidin抗菌肽基因 |
CN1641025A (zh) * | 2004-11-29 | 2005-07-20 | 中国水产科学研究院黄海水产研究所 | 真鲷抗菌肽基因和重组酵母表达载体及其制备方法 |
-
2005
- 2005-12-29 CN CNB2005101210370A patent/CN100402552C/zh not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102140130A (zh) * | 2010-11-12 | 2011-08-03 | 中国科学院海洋研究所 | 一种抗菌肽及其应用 |
CN102140130B (zh) * | 2010-11-12 | 2013-03-27 | 中国科学院海洋研究所 | 一种抗菌肽及其应用 |
CN118252918A (zh) * | 2024-05-27 | 2024-06-28 | 华南农业大学 | 斜带石斑鱼piscidin3及其合成多肽在制备抗鱼类病毒药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100402552C (zh) | 2008-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lin et al. | Identification and phylogenetic analysis on lipopolysaccharide and β-1, 3-glucan binding protein (LGBP) of kuruma shrimp Marsupenaeus japonicus | |
Zhou et al. | Characterization and expression analysis of a chitinase gene (PmChi-4) from black tiger shrimp (Penaeus monodon) under pathogen infection and ambient ammonia nitrogen stress | |
Zhang et al. | Molecular characterization and expression analysis of lipopolysaccharide and β-1, 3-glucan-binding protein (LGBP) from pearl oyster Pinctada fucata | |
Wang et al. | Molecular characterization of a glutathione peroxidase gene and its expression in the selected Vibrio-resistant population of the clam Meretrix meretrix | |
CN101182360B (zh) | 一种具有抗菌功能的融合蛋白及其应用 | |
Vaseeharan et al. | Molecular cloning, sequence analysis and expression of Fein-Penaeidin from the haemocytes of Indian white shrimp Fenneropenaeus indicus | |
CN1238378C (zh) | 一种抗菌肽及其编码序列和用途 | |
CN101550183B (zh) | 一种抗菌肽及其构建和应用 | |
CN1401772A (zh) | 苏云金芽孢杆菌cryl基因、基因组合及表达载体 | |
CN101356191A (zh) | 用于水生生物培养的神经肽 | |
CN1240001A (zh) | 链球菌毒素c突变体及其使用方法 | |
CN1821271A (zh) | 一种抗菌肽及其编码序列和用途 | |
CN101525617A (zh) | 中华绒螯蟹Crustin-1基因及体外重组表达 | |
CN1763092A (zh) | 一种抗菌肽及其编码序列和用途 | |
CN100344758C (zh) | 中国对虾含单一乳清酸性蛋白结构域的抗菌肽基因及其所编码的抗菌肽与应用 | |
CN1908011A (zh) | 一种植物抗逆锌指蛋白及其编码基因与应用 | |
Guo et al. | Functional identification of ToLAAO genes and polymorphism association analysis of Cryptocaryon irritans resistance in Trachinotus ovatus | |
CN102051363A (zh) | 文蛤铁蛋白基因及编码蛋白和其体外重组表达产物的应用 | |
CN109021088A (zh) | 一种斑节对虾抗菌肽ALFpm10及其制备方法 | |
CN103484466A (zh) | 一种小菜蛾抗菌肽moricin及其制备方法与应用 | |
CN102242138B (zh) | 半滑舌鳎抗菌肽hepcidin的重组表达及其应用 | |
CN1236059C (zh) | 一种石斑鱼胰岛素样生长因子ⅱ基因、含有该基因的载体、重组株及其应用 | |
CN1821413A (zh) | 一种表达炭疽杆菌γ噬菌体裂解酶的方法及其专用基因 | |
CN1309824C (zh) | 抗菌肽基因转化的粘质芽胞杆菌工程菌及其制备方法和应用 | |
CN101041691A (zh) | 中国南海信号芋螺神经毒素基因lt5.4及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080716 Termination date: 20101229 |